OS Therapies Incorporated (OSTX) Stock Analysis & Investment Frameworks
OS Therapies Incorporated (OSTX) stock analysis on Invetso. Review OS Therapies Incorporated’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
OS Therapies Incorporated Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
OS Therapies Incorporated Key Financial Metrics
- Market Cap: $46.81M
- Revenue: $N/A
- ROE: 683.03%
- ROIC: 350.07%
- Dividend Yield: N/A
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OS Therapies Incorporated Investment Frameworks
Invetso analyzes OS Therapies Incorporated (OSTX) across the following frameworks:
- OS Therapies Incorporated 10Y Growth Potential
- OS Therapies Incorporated Scenario Analysis
- OS Therapies Incorporated Risks & Opportunities
- OS Therapies Incorporated Economic Moat
- OS Therapies Incorporated Business Model
- OS Therapies Incorporated Management
- OS Therapies Incorporated SWOT Analysis
- OS Therapies Incorporated Porter's 5 Forces
- OS Therapies Incorporated PESTLE Analysis
- OS Therapies Incorporated ESG Analysis